Published in Women's Health Weekly, April 28th, 2005
"The prognostic significance of ITCs in bone marrow from patients with breast carcinoma at the time of their primary diagnosis recently has been confirmed by a large pooled analysis. If the persistence of ITCs after adjuvant therapy confers a similar risk for recurrence, then it would be an indication to consider second," researchers in Germany reported.
"The authors analyzed BM aspirates front 228 patients during recurrence-free follow-up at a median interval ± standard deviation (SD) of 21.3 ± 29.1 months after a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly